Research location

Ningbo

China

Published trials99

Site observations114

Linked trials published99

Page1 / 2

Research activity in Ningbo

China

CureCurrent currently publishes aggregate city-level research activity for this location: 99 trials and 114 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Ningbo

99 linked trials · page 1 of 2

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · 2026-08-26 · 1 site observation

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusNCT07776509 · 2026-08-24 · 1 site observation

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusNCT07662044 · 2026-07-06 · 1 site observation

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMNCT07667803 · 2026-06-29 · 1 site observation

Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.NCT07279935 · 2026-05-26 · 1 site observation

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 · 2026-02-10 · 1 site observation

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011 · 2026-02-10 · 1 site observation

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931 · 2026-02-09 · 1 site observation

A Study of Brenipatide in Adult Participants With Major Depressive DisorderNCT07412756 · 2026-02-09 · 1 site observation

Phase 3b Study in Patients With Severe Asthma Treated With TezepelumabNCT07363642 · 2026-01-28 · 1 site observation

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsNCT07195695 · 2026-01-16 · 1 site observation

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation

The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-managementNCT06909773 · 2025-11-28 · 2 site observations

Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in ChinaNCT07161388 · 2025-11-17 · 1 site observation

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyNCT07472517 · 2025-11-07 · 1 site observation

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884 · 2025-09-30 · 1 site observation

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.NCT07053423 · 2025-09-22 · 1 site observation

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeNCT07190209 · 2025-09-16 · 1 site observation

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT07164443 · 2025-09-02 · 1 site observation

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803 · 2025-08-06 · 1 site observation

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With BenralizumabNCT06862206 · 2025-07-11 · 1 site observation

Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple TherapyNCT07030881 · 2025-06-17 · 3 site observations

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartNCT06935370 · 2025-05-20 · 2 site observations

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyNCT06862869 · 2025-04-30 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277 · 2025-04-10 · 1 site observation

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentNCT06750289 · 2025-03-28 · 1 site observation

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723 · 2025-03-03 · 3 site observations

Remote Anxiety Management for ICS-resistant Asthma StudyNCT06732141 · 2024-12-13 · 4 site observations

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · 2024-11-18 · 1 site observation

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With AsthmaNCT06471257 · 2024-06-17 · 1 site observation

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerNCT06350097 · 2024-04-29 · 1 site observation

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · 2024-04-12 · 1 site observation

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)NCT06210776 · 2024-01-15 · 1 site observation

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationNCT05696626 · 2023-10-31 · 1 site observation

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or OverweightNCT07662122 · 2026-06-30 · 1 site observation

ACTIVE_NOT_RECRUITING

A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）NCT07274137 · 2026-02-01 · 1 site observation

NOT_YET_RECRUITING

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or BehaviorNCT07193901 · 2025-05-27 · 1 site observation

Metabolically Healthy Obesity Increases the Risks of MASLD and HyperuricemiaNCT07001865 · 2025-04-01 · 1 site observation

ENROLLING_BY_INVITATION

A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.NCT06849843 · 2024-12-18 · 2 site observations

Nipocalimab in Moderate to Severe Sjogren's DiseaseNCT06741969 · 2024-12-04 · 1 site observation

ACTIVE_NOT_RECRUITING

CGM-Assisted Community Management for Type 2 DiabetesNCT07097415 · 2024-11-15 · 1 site observation

An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma PatientsNCT06605885 · 2024-11-14 · 1 site observation

ACTIVE_NOT_RECRUITING

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerNCT06616532 · 2024-11-13 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaNCT06676319 · 2024-11-07 · 1 site observation

ACTIVE_NOT_RECRUITING

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · 2024-10-22 · 1 site observation

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsNCT06635447 · 2024-09-26 · 2 site observations

ACTIVE_NOT_RECRUITING

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of ExacerbationsNCT06529419 · 2024-08-30 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.